Recent Finacing
Recent Raise
Alderaan Biotechnology is a Paris-based preclinical immuno-oncology company developing monoclonal antibodies that deplete regulatory T cells (anti-CD25) and activate NK cells (anti-CD160-TM).
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Alderaan Biotechnology.
